1 StoP-AD Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
2 Department of Psychiatry, McGill University, Montréal, QC H3A 1A1, Canada.
3 McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montréal, QC H3A 2B4, Canada.
4 Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montréal, QC H4H 1R3, Canada.
5 Integrated Program in Neuroscience, McGill University, Montréal, QC H3A 0G4, Canada.
6 Research Center of the CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal, Montreal, QC H4J 1C5, Canada.
7 Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
8 Department of Physics, Concordia University, Montréal, QC H4B 1R6, Canada.
9 Department of Neurology and Neurosurgery, McGill University, Montréal, QC H3A 1A1, Canada.
10 Faculté des sciences, Département d'informatique, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
11 Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", NeuroPresage Team, GIP Cyceron, 14032 Caen, France.
12 School of Psychological Science, The University of Western Australia, Perth, Western Australia 6009, Australia.
13 Department Biomedical Engineering, McGill University, Montréal, QC H3A 2B4, Canada.
14 Centre ÉPIC, Montreal Heart Institute, Montréal, QC H1T 1N6, Canada.
15 Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.
16 Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada.
17 Alan Edwards Center for Research on Pain, McGill University, Montreal, QC H3A 2B4, Canada.
18 Department of Psychology, Toronto Metropolitan University, Toronto, ON M5S 2E5, Canada.
19 Clinique interdisciplinaire de mémoire, CHU de Québec affilié à l'Université Laval, Québec, QC G1V 4G2, Canada.
20 Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5H3, Canada.
21 AI2D Center for AI and Data Science for Integrated Diagnostics, University of Pennsylvania, Philadelphia, PA 19104, USA.
22 Psychology Department, Université de Montréal, Montréal, QC H2V 2S9, Canada.
23 Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC H3W 1W5, Canada.
24 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, 431 39 Mölndal, Sweden.
25 Clinical Neurochemistry Lab, Sahlgrenska University Hospital, 43180 Mölndal, Sweden.
26 Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
27 Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, Anhui, 230026 P.R. China.
28 Department of Neurodegenerative Disease, University College London Institute of Neurology, London WC1E 6BT, UK.
29 UK Dementia Research Institute at UCL, London NW1 3BT, UK.
30 Hong Kong Center for Neurodegenerative Diseases, InnoHK, 999077 Hong Kong, China.
31 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA.
32 Department of Physiology and Pharmacology, Université de Montréal, Montréal, QC H3C 3J7, Canada.
33 Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, 224 41 Lund, Sweden.

The PREVENT-AD is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years [median follow-up 8.0 years,SD 3.1]. Multimodal MRI, genetic, neurosensory, clinical, cerebrospinal fluid and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau PET, magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection.